Ai-Qing Li, Shu-Hui Wang, Jun Li, Hong-Tan Chen, Zhen Liu
{"title":"食道神经内分泌癌的人群特异性特征和预后:中西预后图比较。","authors":"Ai-Qing Li, Shu-Hui Wang, Jun Li, Hong-Tan Chen, Zhen Liu","doi":"10.1177/17588359251375454","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Esophageal neuroendocrine carcinoma (ENEC) is a rare, aggressive malignancy with limited comparative data between Eastern and Western populations. Optimal management strategies remain unclear, and prognostic tools for risk stratification are lacking.</p><p><strong>Objectives: </strong>To analyze differences in clinicopathological features, treatment patterns, and survival outcomes between Chinese and American ENEC patients, and to develop a prognostic nomogram for unresectable disease.</p><p><strong>Design: </strong>A retrospective comparative cohort study.</p><p><strong>Methods: </strong>We analyzed 88 ENEC patients from a Chinese institution and 545 from the Surveillance, Epidemiology, and End Results (SEER) database. Demographic, tumor, treatment, and survival data were compared using Chi-square tests and Kaplan-Meier analysis. Cox regression identified prognostic factors for cancer-specific survival. A nomogram for unresectable ENEC was developed using SEER data and evaluated using C-index, calibration curves, and receiver operating characteristic analysis.</p><p><strong>Results: </strong>Significant population differences included age distribution (46-65 years: 51.1% Chinese vs 35.4% SEER, <i>p</i> < 0.001), tumor location (lower esophagus: 22.7% vs 62.2%), histology (small cell: 38.6% vs 76.9%), and metastatic presentation (M1: 28.4% vs 54.1%, all <i>p</i> < 0.01). Among non-metastatic patients, 77.8% Chinese underwent surgery versus 19.2% SEER (<i>p</i> < 0.001). Despite this treatment disparity, median survival was similar for surgical patients (48 vs 32 months, <i>p</i> = 0.93). Metastatic disease and age >65 were independent adverse prognostic factors in both cohorts. The Chinese cohort showed additional prognostic factors including tumor location and histology. The nomogram incorporating age, tumor location, N stage, M stage, and chemotherapy achieved a C-index of 0.725 with excellent calibration at 12 and 24 months.</p><p><strong>Conclusion: </strong>ENEC demonstrates distinct population-specific characteristics between Chinese and Western patients, with fundamental differences in treatment approaches but comparable surgical outcomes. The validated nomogram provides superior risk stratification for unresectable disease compared to traditional staging. These findings support population-tailored management strategies rather than universal treatment paradigms for ENEC.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251375454"},"PeriodicalIF":4.2000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12489240/pdf/","citationCount":"0","resultStr":"{\"title\":\"Population-specific characteristics and outcomes in esophageal neuroendocrine carcinoma: a Chinese-Western comparison with prognostic nomogram.\",\"authors\":\"Ai-Qing Li, Shu-Hui Wang, Jun Li, Hong-Tan Chen, Zhen Liu\",\"doi\":\"10.1177/17588359251375454\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Esophageal neuroendocrine carcinoma (ENEC) is a rare, aggressive malignancy with limited comparative data between Eastern and Western populations. Optimal management strategies remain unclear, and prognostic tools for risk stratification are lacking.</p><p><strong>Objectives: </strong>To analyze differences in clinicopathological features, treatment patterns, and survival outcomes between Chinese and American ENEC patients, and to develop a prognostic nomogram for unresectable disease.</p><p><strong>Design: </strong>A retrospective comparative cohort study.</p><p><strong>Methods: </strong>We analyzed 88 ENEC patients from a Chinese institution and 545 from the Surveillance, Epidemiology, and End Results (SEER) database. Demographic, tumor, treatment, and survival data were compared using Chi-square tests and Kaplan-Meier analysis. Cox regression identified prognostic factors for cancer-specific survival. A nomogram for unresectable ENEC was developed using SEER data and evaluated using C-index, calibration curves, and receiver operating characteristic analysis.</p><p><strong>Results: </strong>Significant population differences included age distribution (46-65 years: 51.1% Chinese vs 35.4% SEER, <i>p</i> < 0.001), tumor location (lower esophagus: 22.7% vs 62.2%), histology (small cell: 38.6% vs 76.9%), and metastatic presentation (M1: 28.4% vs 54.1%, all <i>p</i> < 0.01). Among non-metastatic patients, 77.8% Chinese underwent surgery versus 19.2% SEER (<i>p</i> < 0.001). Despite this treatment disparity, median survival was similar for surgical patients (48 vs 32 months, <i>p</i> = 0.93). Metastatic disease and age >65 were independent adverse prognostic factors in both cohorts. The Chinese cohort showed additional prognostic factors including tumor location and histology. The nomogram incorporating age, tumor location, N stage, M stage, and chemotherapy achieved a C-index of 0.725 with excellent calibration at 12 and 24 months.</p><p><strong>Conclusion: </strong>ENEC demonstrates distinct population-specific characteristics between Chinese and Western patients, with fundamental differences in treatment approaches but comparable surgical outcomes. The validated nomogram provides superior risk stratification for unresectable disease compared to traditional staging. These findings support population-tailored management strategies rather than universal treatment paradigms for ENEC.</p>\",\"PeriodicalId\":23053,\"journal\":{\"name\":\"Therapeutic Advances in Medical Oncology\",\"volume\":\"17 \",\"pages\":\"17588359251375454\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12489240/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Medical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17588359251375454\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17588359251375454","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:食管神经内分泌癌(ENEC)是一种罕见的侵袭性恶性肿瘤,东西方人群的比较资料有限。最佳管理策略仍然不清楚,并且缺乏风险分层的预后工具。目的:分析中国和美国ENEC患者的临床病理特征、治疗模式和生存结果的差异,并为不可切除的疾病制定预后图。设计:回顾性比较队列研究。方法:我们分析了来自中国一家机构的88例ENEC患者和来自监测、流行病学和最终结果(SEER)数据库的545例患者。统计学、肿瘤、治疗和生存数据采用卡方检验和Kaplan-Meier分析进行比较。Cox回归确定了癌症特异性生存的预后因素。使用SEER数据建立不可切除ENEC的模态图,并使用c指数、校准曲线和接收器工作特性分析进行评估。结果:显著的人群差异包括年龄分布(46-65岁:51.1%中国人vs 35.4% SEER, p p p = 0.93)。在两个队列中,转移性疾病和年龄在65岁以下是独立的不良预后因素。中国队列显示了包括肿瘤位置和组织学在内的其他预后因素。包含年龄、肿瘤位置、N分期、M分期和化疗的nomogram C-index为0.725,在12个月和24个月时具有很好的校准性。结论:ENEC在中国和西方患者中表现出明显的人群特异性特征,在治疗方法上存在根本差异,但手术结果相似。与传统分期相比,经验证的nomogram为不可切除疾病提供了优越的风险分层。这些发现支持针对人群的管理策略,而不是针对ENEC的普遍治疗范例。
Population-specific characteristics and outcomes in esophageal neuroendocrine carcinoma: a Chinese-Western comparison with prognostic nomogram.
Background: Esophageal neuroendocrine carcinoma (ENEC) is a rare, aggressive malignancy with limited comparative data between Eastern and Western populations. Optimal management strategies remain unclear, and prognostic tools for risk stratification are lacking.
Objectives: To analyze differences in clinicopathological features, treatment patterns, and survival outcomes between Chinese and American ENEC patients, and to develop a prognostic nomogram for unresectable disease.
Design: A retrospective comparative cohort study.
Methods: We analyzed 88 ENEC patients from a Chinese institution and 545 from the Surveillance, Epidemiology, and End Results (SEER) database. Demographic, tumor, treatment, and survival data were compared using Chi-square tests and Kaplan-Meier analysis. Cox regression identified prognostic factors for cancer-specific survival. A nomogram for unresectable ENEC was developed using SEER data and evaluated using C-index, calibration curves, and receiver operating characteristic analysis.
Results: Significant population differences included age distribution (46-65 years: 51.1% Chinese vs 35.4% SEER, p < 0.001), tumor location (lower esophagus: 22.7% vs 62.2%), histology (small cell: 38.6% vs 76.9%), and metastatic presentation (M1: 28.4% vs 54.1%, all p < 0.01). Among non-metastatic patients, 77.8% Chinese underwent surgery versus 19.2% SEER (p < 0.001). Despite this treatment disparity, median survival was similar for surgical patients (48 vs 32 months, p = 0.93). Metastatic disease and age >65 were independent adverse prognostic factors in both cohorts. The Chinese cohort showed additional prognostic factors including tumor location and histology. The nomogram incorporating age, tumor location, N stage, M stage, and chemotherapy achieved a C-index of 0.725 with excellent calibration at 12 and 24 months.
Conclusion: ENEC demonstrates distinct population-specific characteristics between Chinese and Western patients, with fundamental differences in treatment approaches but comparable surgical outcomes. The validated nomogram provides superior risk stratification for unresectable disease compared to traditional staging. These findings support population-tailored management strategies rather than universal treatment paradigms for ENEC.
期刊介绍:
Therapeutic Advances in Medical Oncology is an open access, peer-reviewed journal delivering the highest quality articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in medical oncology, providing a forum in print and online for publishing the highest quality articles in this area. This journal is a member of the Committee on Publication Ethics (COPE).